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Abstract
Background: Diagnosis of primary HIV infection (PHI) has important clinical and public health implications. HAART
initiation at this stage remains controversial.
Methods: Our objective was to identify predictors of disease progression among Argentinean seroconverters
during the first year of infection, within a multicentre registry of PHI-patients diagnosed between 1997 and 2008.
Cox regression was used to analyze predictors of progression (LT-CD4 < 350 cells/mm
3, B, C events or death) at 12
months among untreated patients.
Results: Among 134 subjects, 74% presented with acute retroviral syndrome (ARS). Seven opportunistic infections
(one death), nine B events, and 10 non-AIDS defining serious events were observed. Among the 92 untreated
patients, 24 (26%) progressed at 12 months versus three (7%) in the treated group (p = 0.01). The 12-month
progression rate among untreated patients with ARS was 34% (95% CI 22.5-46.3) versus 13% (95% CI 1.1-24.7) in
asymptomatic patients (p = 0.04). In univariate analysis, ARS, baseline LT-CD4 < 350 cells/mm
3, and baseline and
six-month viral load (VL) > 100,000 copies/mL were associated with progression. In multivariate analysis, only ARS
and baseline VL > 100,000 copies/mL remained independently associated; HR: 8.44 (95% CI 0.97-73.42) and 9.44
(95% CI 1.38-64.68), respectively.
Conclusions: In Argentina, PHI is associated with significant morbidity. HAART should be considered in PHI
patients with ARS and high baseline VL to prevent disease progression.
Background
Cohort studies addressing primary HIV infection (PHI)
have been used as a tool to study the natural history of
HIV and to estimate the incidence of AIDS-defining
events, as well as other non-associated AIDS comorbid-
ities. It is increasingly recognized that early host-virus
interactions may influence the later course of disease
[1,2]. Therefore, follow up of patients immediately after
seroconversion may help identify prognostic markers
useful in the evaluation of therapeutic approaches.
To date, most studies of HIV seroconverters have
been performed in Europe or North America [3-5].
Scarce information exists on this issue from resource-
limited settings, particularly in South America, where
there are different host, social and viral (i.e., subtype)
characteristics that may alter the course of HIV infec-
tion [6-8].
In Argentina, it is estimated that there are approxi-
mately 130,000 persons living with HIV/AIDS, but only
half of them are aware of their status. In 2008, more
than 4000 new HIV infections were reported [9]. How-
ever, information regarding patients diagnosed during
the early stages of infection is limited. To address this * Correspondence: eugenia_socias@yahoo.com.ar
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HIV infection in Argentina was started in 2008 [10,11].
This paper describes the epidemiological, clinical,
immunological and virological characteristics of the first
134 patients enrolled in our cohort with the aim of
identifying potential markers associated with HIV
progression.
Methods
Study population
Grupo Argentino de Seroconversión [10,11] is an ongoing
multicentre Argentine observational cohort of patients
diagnosed during primary HIV infection. This cohort
was started in 2008 and includes two data sets: the first
one includes patients diagnosed between 1997 and 2007,
and the second prospectively follows patients diagnosed
after January 2008.
Inclusion criteria for enrolment in the cohort are: age
> 16 years at first evaluation, confirmed diagnosis of pri-
mary HIV infection, and first medical and laboratory
evaluation (i.e., CD4 cell count and plasma HIV RNA)
within six months of the probable date of infection. Pri-
mary HIV infection is defined as: (1) detection of HIV
RNA or p24 antigen with a simultaneous negative or
indeterminate Western blot assay [12]; or (2) positive
Western blot with a negative test within the previous six
months Hence, it includes both acute and recent HIV-
infection patients.
Structured questionnaires are used for baseline and fol-
low-up visits. Clinical and laboratory information is
updated every six months until death or loss to follow up.
In this paper, we report on patients who were diag-
nosed up to 31 December 2008. Analysis of disease pro-
gression was limited to the first year of infection.
Ethical considerations
The Grupo Argentino de Seroconversión study protocol
was approved by the Huésped Foundation Ethics Com-
mittee. All patients followed prospectively signed written
informed consent before enrolment. Patients studied ret-
rospectively signed consent at their first follow-up visit,
if still alive.
Definitions
We defined PHI as “symptomatic” if one or more symp-
toms associated with acute retroviral syndrome were
present [13,14]. “Severe symptomatic PHI” was defined
as presence of B or C events, (according to the Centers
for Disease Control and Prevention 1993 classification
[15]), any other serious non-AIDS-related events, or
death at the time of HIV seroconversion.
In symptomatic patients, the date of infection was esti-
mated as 14 days before the onset of symptoms. In
asymptomatic patients, the date of infection was
estimated as the midpoint between the last negative and
the first positive test or one month before the date of the
indeterminate or negative Western blot assay [16-18].
HIV progression was defined either by clinical (B or C
events [15]), or immunological (CD4 cell count < 350
cells/mm
3) criteria, whichever occurred first. We chose
these endpoints based on the current national and inter-
national recommendations for initiation of antiretroviral
therapy [19,20]. Analysis of disease progression was lim-
ited to those patients who did not start treatment within
the first 120 days of infection.
Statistical analysis
Quantitative variables were described using mean and
standard deviation (SD) in cases where the underlying
distribution was normal; median and interquartile
ranges (IQR) were used for variables without normal
distribution. Differences were analyzed using Student’s
t-test for independent samples or the non-parametric
Wilcoxon Rank Sum test.
Categorical variables were described using proportions
and percentages. Differences between proportions were
analyzed with the Chi-square test, or Fisher’s exact test.
Differences were considered statistically significant for p
< 0.05, two-tailed tests. Univariate analysis was per-
formed for the variables hypothesized as risk factors for
events under study. All the variables of interest for the
study were included in the multivariate analysis. Cox
regression analysis was performed and the hazard risk
(HR), 95% confidence interval (CI) and p value were cal-
culated for each variable.
Progression-free survival time was measured from the
estimated date of infection to the date of progression.
For those patients who did not experience an event,
data was censored at their last visit within their first
year of infection or at treatment initiation. Time until
an event was studied using Kaplan-Meier survival analy-
sis, and the log rank test was applied for significance.
Overall median time estimates, as well as median time
by arm and corresponding 95% CI, are given. Kaplan-
Meier plots are shown. Data analysis was performed
with SPSS 15.0, 2007 (Chicago, Illinois).
Results
Baseline characteristics
As of December 2008, 134 patients with primary HIV
infection were enrolled in the cohort; 99 retrospectively
and 35 prospectively. Baseline characteristics are sum-
marized in Table 1. Most patients were male (n = 109)
with a median age of 32 years (IQR 25-39). More than
half of the patients (53%) defined themselves as men
who have sex with men (MSM), while 50 (37%) reported
heterosexual exposure. Only one patient reported intra-
venous drug use as the probable route of infection.
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city and its surroundings suburbs, areas that concentrate
44% of people living with HIV/AIDS in Argentina [9].
Seventy-five percent of patients completed at least high
school and 29% were unemployed. HIV testing was
requested based on a physician’s clinical suspicion in
48% of cases and because of patient’s request in 33% of
cases. In 18% of cases, HIV seroconversion was diag-
nosed in patients undergoing periodic HIV testing. Of
note, three patients were diagnosed during pregnancy.
The source of transmission could be identified in 52
cases. In 28 (54%) of these, a stable HIV-positive partner
was identified.
At first evaluation, the Western blot test was negative
in 12 patients (9%) and indeterminate in 53 (40%). In 26
of these cases, a virologic test (p24 antigen or HIV viral
load) defined the diagnosis. All cases with initial nega-
tive or indeterminate Western blot had HIV infection
confirmed by subsequent seroconversion. The remaining
69 (51%) patients with a reactive Western blot had a
negative test within the previous six months.
The first laboratory evaluation (HIV viral load and
CD4 cell count) was done at a median of 66 days (IQR
48-112) after the probable date of exposure to HIV.
Median HIV-1 RNA VL was 4.87 log10 copies/mL (IQR
4.11-5.51) and the median absolute and percentage CD4
cell count were 479 cells/mm
3 (IQR 341-682) and 23%
(IQR 17-28), respectively. Baseline CD4 cell counts were
<3 5 0a n d<2 0 0c e l l s / m m
3 in 27% and 6.25% of
patients, respectively. A total of 42 patients (31%)
started HAART during the acute phase, with a median
time of 84 days (IQR 53-110), from the probable date of
infection: 39 due to symptomatic infection, and in three
asymptomatic cases, due to pregnancy. Since indication
of HAART during PHI is considered optional in Argen-
tina [20], the decision on whether to start treatment or
not depended on the physician in charge.
Morbidity and mortality associated with acute HIV
infection
Ninety-nine patients (74%) presented with acute retro-
viral syndrome, lasting a median of 16 days (IQR 8-29).
Twenty-six of them developed severe symptoms: seven
opportunistic infections (three Pneumocystis jiroveci
pneumonia, one histoplasmosis, one cryptococcal
meningitis, one esophageal candidiasis and one pul-
monary TB); nine B events (thrush, herpes zoster) and
10 non-AIDS defining severe events. The latter
included aseptic meningitis, rhabdomyolysis with
multi-organ failure, acute hepatitis, Bell’s paralysis and
guttate psoriasis.
Thirty-five patients (26.2%) required hospital admis-
sion. One patient developed chronic hydrocephaly
and cognitive impairment secondary to cryptococcal
meningitis and another suffered fatal disseminated
histoplasmosis.
Table 1 Baseline characteristics of Grupo Argentino de Seroconversión cohort (N = 134)
Characteristic All (N = 134) Symptomatic PHI p
YES (n = 99) NO (n = 35)
Age at HIV diagnosis, mean years (SD) 33.4 (10.7) 33.8 (10.37) 32.2 (11.64) 0.44
Male sex, n (%) 109 (81.3) 79 (79.8) 30 (85.8) 0.61
High school education or more, n (%) 79 (75.2) 59 (72.8) 20 (83.4) 0.3
Born in Buenos Aires, n (%) 74 (67.9) 56 (67.5) 18 (69.2) 0.61
Employed, n (%) 82 (70.7) 62 (70.5) 20 (71.4) 0.89
Reason for HIV test, n (%)
Physician’s suspicion 61 (48.4) 56 (59.6) 5 (15.6) < 0.001
Patient request 42 (33.3) 27 (28.7) 15 (46.9)
Routine 23 (18.3) 11 (11.7) 12 (37.5)
Risk factor for HIV transmission, n (%)
MSM 71 (53) 51 (51.5) 20 (57.1) 0.788
Heterosexual 50 (37.3) 38 (38.4) 12 (34.3)
IDU 1 (0.7) 1 (1) 0 (0)
Missing 12 (9) 9 (9) 3 (8.6)
HIV RNA, median log10 copies/mL
(IQR)
4.87
(4.11-5.51)
5.12
(4.49-5.69)
4.36
(3.43-4.95)
< 0.001
CD4 cell count, median cells/mm
3
(IQR)
479
(341-682)
466
(327-609)
533
(425-814)
0.019
HAART initiation, n (%) 42 (31.3) 39 (39.4) 3 (8.6) 0.003
MSM-men who have sex with men; IDU-injection drug user; HAART-highly active antiretroviral therapy
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version were CD4 cell counts lower than 350 cell/mm
3
(p = 0.001) and viral loads higher than 100,000 copies/
mL (p = 0.001). HIV testing was requested more fre-
quently by physicians based on clinical suspicion rather
than patients’ initiative (OR 5.06; 95% CI 1.83-14.04).
We found no association between age, gender, birth
place, risk factor or year of diagnosis with regard to
severity of symptoms (Table 2).
12-month morbidity and mortality
Untreated patients
Among the ninety-two patients who did not start
HAART during acute HIV infection, 24 (26%, 95% CI:
17.5-36.3) patients presented with disease progression
within the first year of infection: 12 had clinical progres-
sion (five AIDS-defining events and seven B events) and
12 exhibited immunological progression (CD4 cell count
< 350 cells/mm
3). The median time between the prob-
able date of infection and the event presentation was
182 days (IQR 67-233). One patient who developed a
non-Hodgkin lymphoma within six months of HIV
infection died shortly after diagnosis.
Among untreated patients, progression was observed
in 20 out of 60 symptomatic patients and in 4 out of 32
asymptomatic patients. Using Kaplan-Meier curves, esti-
mated rates of progression at 12 months of follow up
were 34% (95% CI 22.5-46.3%) among symptomatic
untreated patients versus 13% (95% CI 1.1- 24.7%) in
the asymptomatic group. The difference between
the two curves was statistically significant (p = 0.04)
(Figure 1). The hazard ratio of disease progression for
untreated persons with symptomatic primary HIV infec-
tion compared with asymptomatic seroconverters was
8.44 (95% CI 0.97-73.42).
Factors associated with faster progression among
untreated patients during the first year of infection were
symptomatic primary HIV infection (p = 0.046), higher
viral load at baseline and at six months from serocon-
version (p = 0.04 and 0.008, respectively), as well as
lower baseline CD4 cell count (p = 0.002). No
association was found with age at seroconversion, gen-
der, mode of HIV acquisition and year of infection. In
the multivariate analysis (Table 3), only symptomatic
primary HIV infection (p = 0.049) and baseline viral
load higher than 5 log10 copies/mL (p = 0.022) remained
as independent predictors of faster progression; relative
risks 8.44 (95% CI 0.97-73.42) and 9.44 (95% CI 1.38-
64.68), respectively. Baseline CD4 and viral load at six
months were no longer associated with increased risk of
progression in the multivariate model.
Evolution among treated patients
Among those patients who started HAART within the
first 120 days of HIV infection, only three (7%) pre-
sented with HIV progression (one C event, one B event
and one CD4 cell count decrease to < 350 cells/mm
3
despite HAART initiation) within the first year of infec-
tion. The difference to the 26% progression rate seen in
the untreated group was statistically significant (p =
0.01). Of note, the C event was pulmonary TB, which is
endemic in Argentina.
Discussion
T h i ss t u d yi st h ef i r s tr e p o r tf r o mt h eo n l ym u l t i c e n t r e
cohort of HIV seroconverters in Argentina and one of
the few descriptions of HIV-1 progression from sero-
conversion in Latin America.
In our cohort, the proportion of patients with sympto-
matic disease was similar to previous series [13,17,21,22].
Of note, one-quarter presented with serious clinical man-
ifestations associated with seroconversion. Even though
these have been previously reported [23-26], our results
regarding the relatively high frequency of serious clinical
manifestations during primary HIV infection are rather
unusual. In our study, severe PHI was strongly associated
with higher baseline viral load and low CD4 cell count,
which is also consistent with other reports [27-29]. Like-
wise, during acute HIV infection, opportunistic infections
are usually associated with low CD4 cell count. In our
study, however, four out of five AIDS-defining events
registered after the first 60 days of HIV infection were
associated with CD4 counts greater than 200 cells/mm
3
(Table 4), thereby highlighting the need to consider
opportunistic infection even in patients with moderate
immune deficiency.
Most of our patients were young males, with MSM
being slightly overrepresented compared with the cur-
rent proportion in the local HIV epidemic, where het-
erosexual intercourse is the most common mode of HIV
transmission [9]. Greater awareness regarding acute ret-
roviral syndrome (ARS), the higher frequency of testing
among this population, and the inclusion in the cohort
of a voluntary counselling and testing centre, where
most of the attendants are MSM, could have influenced
our results. In addition, medical prejudice could have
Table 2 Factors associated with severe symptomatic PHI
(univariate analysis) (n = 26)
Risk factor OR (95%CI) p
Age at seroconversion > 30 years 1.36 (0.63-2.92) 0.495
Male sex 2.52 (0.63-10.04) 0.246
Mode of HIV transmission (MSM) 1.14 (0.51-2.55) 0.58
Diagnosis based on physician suspicion 5.06 (1.83-14.04) < 0.001
CD4 cell count < 350 cells/mm
3 3.72 (1.83-7.58) 0.001
HIV RNA > 100,000 copies/mL 3.72 (1.58-8.77) 0.001
Year of diagnosis ≥ 2005 0.79 (0.37-1.70) 0.619
MSM-men who have sex with men
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than in the heterosexual population. This could also
partly explain the lower proportion of women in our
cohort compared with Argentina’so v e r a l lH I Vp o p u l a -
tion [9] (19% vs. 39%), limiting the generalization of our
findings.
One-quarter of the patients who did not start HAART
during the acute phase met clinical or immunological
criteria (< 350 CD4 cells/mm
3) [19,20] to initiate
HAART during the first year of HIV infection. This
observation is particularly relevant as one-third of the
patients were already excluded in the progression analy-
sis due to HAART initiation during the acute HIV
phase, which resulted in the exclusion of a considerable
proportion of symptomatic patients with risk of progres-
sion. The progression rate described here is much
higher than in earlier epidemiological reports [30],
which estimated a window of several years before the
13% 
34% 
p=0.04 
Figure 1 Time to progression of HIV disease among untreated patients from the Grupo Argentino de Seroconversión. Progression-free
survival from onset of HIV infection among untreated patients with or without symptomatic primary HIV infection.
Table 3 Predictors of disease progression in untreated patients (unadjusted and adjusted analysis) (n = 92)
Risk factor Unadjusted HR (95%CI) p Adjusted HR (95%CI) p
Symptomatic PHI 1.41 (1.08- 1.83) 0.046 8.44 (0.97-73.42) 0.049
Age at seroconversion > 30 years 1.40 (0.93- 2.10) 0.159 4.42 (0.91-21.47) 0.065
Mode of HIV transmission (MSM) 1.38 (1.02-1.86) 0.081 0.99 (0.11-8.64) 0.995
Baseline CD4 cell count ≤ 350 cell/mm
3 3.81 (1.64-8.86) 0.002 3.14 (0.47-20.78) 0.236
Baseline HIV RNA ≥ 100,000 copies/mL 1.91 (1.08-3.39) 0.043 9.44 (1.38-64.68) 0.022
HIV RNA at 6 months ≥ 100,000 copies/mL 9.88 (1.30-75.20) 0.008 2.24 (0.19-26.14) 0.520
Male sex 1.07 (0.89-1.29) 0.752 3.33 (0.16-67.54) 0.433
Year of diagnosis ≥ 2005 0.81 (0.61-1.09) 0.146 2.10 (0.20-21.99) 0.537
PHI-primary HIV infection; MSM-men who have sex with men
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CASCADE cohort investigators [31] found that nearly
30% of their patients had ≤ 500 CD4 cells/mm
3 12
months after infection.
Symptomatic PHI and baseline HIV RNA > 100,000
copies/mL were identified in our study as predictors of
disease progression in the multivariate model. These
findings are consistent with prior studies [2,3,28,29,32].
While high viral loads during acute HIV infection are
typically described [33,34], low plasma levels of HIV
RNA have also been reported [7,35]. Comparisons
across cohorts are difficult. However, an interesting
finding of our study was that compared with European
and North American cohorts of seroconvertors [3,4],
baseline HIV RNA was higher and closer to levels seen
in reports from African [8] and Asian [2] countries.
Although some differences in early laboratory values
may be accounted for by differences in the quantitative
methods used or the length of seroconversion intervals,
first viral load measurement in our cohort was done at a
median of 66 days from the probable date of infection,
similar to most of the published studies [2-4,8]. There is
growing evidence that initial viral load measurements, as
well as the subsequent course of HIV infection, may be
affected by viral [36-39] and host factors, including age,
gender [40,41], race [42] and genetics [43,44].
In our cohort, the relative risk of disease progression
in patients with baseline viral loads of > 100,000 copies/
mL was almost 10-fold. Taking into account that more
than 40% (59/134) of the patients enrolled in our cohort
presented with initial viral load levels above this
threshold, the impact of this finding as a prognostic fac-
tor on the subsequent course of infection deserves to be
highlighted. Viral load at six months, however, did not
correlate with progression; likewise, neither did CD4 cell
count at baseline or six months, which underscores the
need to identify other markers of progression at this
early stage of infection.
Recent evidence suggesting an increase in HIV viru-
lence over time [31,45-47] could not be corroborated, as
patients who seroconverted before or after 2005 pre-
sented with similar median CD4 cell count (481 cells/
mm
3 vs. 477 cells/mm
3; p = NS) and disease progression
(p = 0.537). However, the relatively small size of our
cohort prevents us from formulating definite conclu-
sions on this topic.
Our study has several limitations. First, it is possible
that current clinical practice in Argentina limited identi-
fication to only the most symptomatic patients, which
could have contributed to the faster progression seen in
our cohort. In our country, universal access to HIV test-
ing is guaranteed by law, but there are structural, social
and economic barriers to access. It is estimated that at
least 50% of infected people still remain unidentified [9].
Except for antenatal care, testing is usually conducted in
specialized centres. HIV testing in emergency rooms, for
example, is usually not accessible. These practices could
have resulted in HIV testing being requested only in
those patients with a more severe clinical picture, or
with evident epidemiological risk. Although we cannot
rule out this possibility, 26% of patients in our cohort
were asymptomatic.
Table 4 AIDS-defining events during the first year of infection
Subject Event Time from HIV infection to event
(days)
CD4 cell count (cells/
mm
3)
Outcome
1 PCP 15 27 Resolved, HAART initiated
2 PCP 15 13 Resolved, HAART initiated
3 Cryptococcal
meningitis
60 227 Cognitive impairment secondary to chronic
hydrocephaly
4 Disseminated
histoplasmosis
32 42 Death
5 Esophageal
candidiasis
9 134 Resolved, HAART initiated
6 Pulmonary TB 28 419 Resolved with TB treatment
7 PCP 25 199 Resolved, HAART initiated
8 Cytomegalovirus
disease
92 278 Resolved, HAART initiated
9 Non-Hodgkin
lymphoma
210 28 Death
10 Pulmonary TB 203 553 Resolved with TB treatment
11 Cryptosporidiosis 120 570 Resolved
12 Kaposi’s sarcoma 230 828 Resolved, HAART and quimiotherapy initiated
PCP-Pneumocystis jiroveci pneumonia; TB-tuberculosis
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HAART during PHI, and were therefore excluded from
the analysis. This could have lead to a more conserva-
tive estimate of the risk of disease progression. Third,
inclusion of patients with different seroconversion inter-
vals (i.e., acute and recent HIV infection) could have
influenced our results. However, we compared rates of
progression between pre- and post-seroconversion
patients and found no meaningful differences (32% vs.
22%; p = 0.39).
In addition, due to the retrospective-prospective
design of this study and the availability of stored blood
samples only for a subset of patients enrolled after 2008,
we could not study biological factors affecting immune
dysregulation, such as viral tropism [39,48], specific
HLA haplotypes [48,49] and regulatory T cells [50,51].
Our research group is currently conducting other stu-
dies to understand the role of these biologic factors in
the course of HIV infection.
Finally, information regarding viral subtype and geno-
typic analysis were not available for all patients and
therefore it is not presented here. It is possible that HIV
subtype could influence viral load set point and subse-
quent course of HIV infection [36-38]. We are currently
studying the potential influence of the two most preva-
lent subtypes of HIV-1, B and BF [52-56], on disease
progression in our country.
Conclusions
In conclusion, the data presented here have direct impli-
cations for providing HIV care in Argentina. First, acute
retroviral syndrome was associated with faster progres-
sion, significant morbidity and, in some cases, with
HIV-associated mortality. Therefore, awareness needs to
be raised among physicians to include HIV in their dif-
ferential diagnosis of febrile illness, especially in high-
risk groups, such as serodiscordant couples, sexual
workers, injection drug users and MSM. Likewise, HIV
should be considered in any sexually active person who
presents in the emergency room with flu-like syndrome
as nearly 1% of them may have acute HIV infection
[57,58].
Furthermore, this data should be taken into considera-
tion when making decisions on treatment initiation.
Patients with acute retroviral syndrome or high baseline
viral load should be considered for treatment initiation,
as our data suggest that approximately one-third of
them will require treatment in the following year; new
evidence also suggests benefits of earlier treatment
initiation [59,60].
Combined with other ongoing research in this field,
the data presented here could provide valuable informa-
tion on the complex interplay between virus and
host factors in HIV pathogenesis that could aid in the
development of better algorithms, new therapeutic
approaches and the design of preventive interventions.
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